<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264223</url>
  </required_header>
  <id_info>
    <org_study_id>KLBIO 07-10-14</org_study_id>
    <nct_id>NCT02264223</nct_id>
  </id_info>
  <brief_title>The Bioavailability of Red Clover Isoflavones</brief_title>
  <acronym>KLBIO</acronym>
  <official_title>The Effects of Processing and Matrices on Bioavailability of Red Clover Isoflavones in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Danish University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herrens Mark A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Natur Drogeriet A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Future Food Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous literature has shown that the molecular form of isoflavones (as aglycones or
      glycosides) and food matrices can influence the bioavailability of these compounds in humans
      and hence their efficacy. To determine the effects of processing and food matrices on the
      bioavailability of active compounds derived from red clover the investigators will execute a
      5 phase, cross-over design, open label, RCT using 20 healthy women aged between 18 to 40
      years. Participants will receive 5 different formulations of red clover and bioavailability
      will be monitored in blood plasma using LC-MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to elucidate the effects food matrices and processing on the
      bioavailability of active compounds on the bioavailability of red clover derived isoflavones.
      20 healthy participants will receive red clover derived isoflavones in five different
      formulations. The five formulations are split up into five phases:

      Phase 1) Fermented extract in liquid form Phase 2) Fermented extract (freeze-dried) in
      capsule form Phase 3) Fermented extract (freeze-dried) in tablet form Phase 4) Fermented
      extract (concentrated) mixed in yogurt Phase 5) Un-fermented red clover in capsule or tablet
      form The trial will last 5-6 weeks for each participant. Plasma sample collection will take
      place both pre-and post- ingestion of a formulation, participants will receive blood tests at
      intervals -15 min, 0 min, 2hr, 4hr, 6hr, 8hr and 12hr (on the day of ingestion) and on the
      subsequent two mornings (24hr and 48hr) following the initiation of a phase. There will be a
      minimum. 5 day intervals between all phases (washout periods). Isoflavones biochanin A,
      formononetin, genistein and daidzein present in plasma will be detected using HPLC-MS for
      each phase, thus creating a bioavailability curve that can be compared to each of the other
      phases. The primary endpoint is to determine whether fermented extract is more bioavailable
      than unfermented extract.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of isoflavones in terms of fermented vs unfermented formulations</measure>
    <time_frame>-15min, 0hr, 2hr, 4hr, 6hr, 8hr, 12hr, 24hr, 48hr</time_frame>
    <description>As measured by iAUC plasma concentrations of isoflavones over 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of isoflavones in terms of matrices (tablet, capsule, yoghurt and liquid)</measure>
    <time_frame>-15min, 0hr, 2hr, 4hr, 6hr, 8hr, 12hr, 24hr, 48hr</time_frame>
    <description>As measured by iAUC plasma concentrations of isoflavones over 48 hours</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Capsule (aglycone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.
Fermented red clover isoflavones in aglycone form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet (aglycone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.
Fermented red clover isoflavones in aglycone form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yoghurt (aglycone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt
Fermented red clover isoflavones in aglycone form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid extract (aglycone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid
Fermented red clover isoflavones in aglycone form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet unfermented (glycoside)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones
Unfermented glycosides (as aglycone equivalents)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fermented red clover isoflavones in aglycone form</intervention_name>
    <description>Fermented isoflavones in aglycone form</description>
    <arm_group_label>Capsule (aglycone)</arm_group_label>
    <arm_group_label>Tablet (aglycone)</arm_group_label>
    <arm_group_label>Yoghurt (aglycone)</arm_group_label>
    <arm_group_label>Liquid extract (aglycone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Unfermented glycosides (as aglycone equivalents)</intervention_name>
    <description>Unfermented aglycone equivalents in glycoside form</description>
    <arm_group_label>Tablet unfermented (glycoside)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy women

          -  Age: 18-40 years

        Exclusion Criteria:

          -  Habitual intake of soy products, chickpeas or other supplements with a high content of
             isoflavones

          -  Hormone therapy

          -  Pregnant or breastfeeding

          -  Taking drugs affecting uptake

          -  Participation in other clinical trials within the last 3 months

          -  Severe cardiovascular, psychiatric, neurological and / or kidney disease

          -  Alcohol or substance abuse

          -  Acute illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per B Jeppesen, Prof. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Central Jutland Region</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Per Bendix Jeppesen</investigator_full_name>
    <investigator_title>Associate Prof., PhD</investigator_title>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Isoflavones</keyword>
  <keyword>Plasma</keyword>
  <keyword>Human</keyword>
  <keyword>Processing</keyword>
  <keyword>Cross-over</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Glycosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

